Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a ...

Syndax has also tested the drug in AML driven by mutations to the NPM1 gene. The company is planning a first half 2025 regulatory submission seeking to expand the drug’s approval to AML driven ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

This group, combined with NPM1 mutation-positive (NPM1-m) patients, who make up about 30% of AML cases, has been in urgent need of innovative treatment options. Kura Oncology's ziftomenib is also ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...